Nurix Therapeutics (NRIX) has shared an announcement.
Nurix Therapeutics has revealed promising updated clinical data from its Phase 1 trial of NX-5948 at the European Hematology Association Congress. The drug, aimed at treating chronic lymphocytic leukemia (CLL), showed a 69.2% objective response rate among patients, with early and deepening responses over time. Despite a heavily pretreated patient group with common resistance mutations and poor prognostic features, NX-5948 was well tolerated and effective across various doses.
Find detailed analytics on NRIX stock on TipRanks’ Stock Analysis page.
